2025-12-21 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data provided.

## TransMedics Group Inc. (TMDX) Report

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care systems for transplantation.

**1. Return Rate Comparison:**

*   **TMDX Cumulative Return:** 214.22%
*   **S&P 500 (VOO) Cumulative Return:** 76.12%
*   **Divergence:** 138.1%
*   **Relative Divergence:** 64.4

**Analysis:**

TMDX has significantly outperformed the S&P 500 over the specified period. The divergence is substantial, indicating that TMDX's stock performance has been much stronger. The relative divergence of 64.4 suggests the divergence is not at the extreme high end of its historical range, leaving room for further potential outperformance or a correction.

**Alpha, Beta Analysis:**

|            Year |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|----------------:|-------:|------:|--------:|-------:|---------:|
|     2019-2021   | -18.0% | 83.5% | -61.0%  | -0.0   |      0.7 |
|     2020-2022   |  94.0% | 83.5% |  95.0%  |  0.0   |      2.1 |
|     2021-2023   |  65.0% | 80.5% |  64.0%  |  0.1   |      2.7 |
|     2022-2024   | 130.0% | 85.5% | 109.0%  |  0.1   |      2.1 |
|     2023-2025   | 135.0% | 85.5% |  70.0%  |  0.3   |      4.4 |

**Analysis:**

*   **CAGR:**  The CAGR (Compound Annual Growth Rate) shows significant variability year to year, with negative returns in the 2019-2021 period and strong growth in subsequent periods. The last two periods (2022-2024 and 2023-2025) have shown very strong CAGRs exceeding 130%.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating that the stock is subject to significant price drops.
*   **Alpha:** The Alpha values are very high for all periods except 2019-2021 indicating the stock's excess return relative to the market is high.
*   **Beta:**  The Beta values are consistently low, suggesting that the stock is relatively less sensitive to market movements than the S&P 500.
*   **Cap(B):** Market Cap has been increasing over time.

**2. Recent Stock Price Fluctuations:**

*   **Close:** 127.67
*   **Previous Close:** 121.07
*   **Change:** 5.45
*   **5-day SMA:** 123.77
*   **20-day SMA:** 134.25
*   **60-day SMA:** 124.88

**Analysis:**

The stock price has shown a recent uptick, with a noticeable increase from the previous close. The 5-day SMA is below both the 20-day and 60-day SMAs, suggesting a short-term upward trend following a period where it was possibly underperforming. The 20-day SMA being above the 60-day SMA implies a medium-term upward trend as well.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 25.77 (Oversold)
*   **PPO:** -1.42
*   **Hybrid Signal:** Buy 100% (Very Safe, MRI: 0.90)
*   **Recent (20 days) relative divergence change:** -7.1 (Short-term decline)
*   **Expected Return:** 49.8%

**Analysis:**

*   **MRI:** The MRI suggests a medium level of investment risk.
*   **RSI:** An RSI of 25.77 indicates that the stock is currently oversold, which could potentially signal a buying opportunity.
*   **PPO:** The PPO (Percentage Price Oscillator) is negative, suggesting that the short-term moving average is below the long-term moving average, which can indicate a downtrend.
*   **Hybrid Signal:**  Despite the PPO, the "Hybrid Signal" is recommending a "Buy" position, driven by the MRI of 0.90.
*   **Relative Divergence:**  The recent decrease in relative divergence suggests some short-term weakness in the stock's performance compared to the S&P 500.
*   **Expected Return:** The projected 49.8% expected return is substantial, indicating strong potential for long-term investment.

**4. Recent News & Significant Events:**

*   **Positive Sentiment:** Several news articles highlight positive analyst opinions and increased stock positions by investment firms. Zevenbergen Capital Investments LLC and Texas Permanent School Fund Corp increased their holdings. Analysts are bullish on healthcare stocks, including TMDX.
*   **Mixed Sentiment:** One article mentions that TMDX stock fell despite Q3 earnings beating estimates, suggesting market concerns beyond the immediate financial results. Another article suggests that some MedTech stocks, including TMDX, might lose steam in 2026.
*   **Insider Sales:** There is a report on recent insider sales, which could be interpreted negatively but needs further context (e.g., the scale of sales, reasons behind them).

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:** $144.73 (Avg), $170.00 (High), $114.00 (Low)
*   **Opinions:** 11
*   **Recent Rating Changes:** Not available (Indicates no recent changes were provided.)

**Analysis:** The analyst consensus is a "Buy" with a mean rating suggesting a strong positive outlook. The average target price of $144.73 suggests potential upside from the current price of $127.67.

**5. Comprehensive Analysis:**

TransMedics Group Inc. (TMDX) has demonstrated exceptional growth and significantly outperformed the S&P 500.  The strong CAGRs and high Alpha values in recent periods support this. While the stock has a high MDD and is prone to volatility, recent positive news and analyst ratings suggest continued positive sentiment. The RSI indicates it may be oversold presenting a buying opportunity.

**Key Considerations:**

*   **High Growth, High Volatility:** TMDX is a high-growth stock with significant volatility, as reflected by its high MDD. Investors should be prepared for potential price swings.
*   **Analyst Optimism:**  Analysts are generally bullish on TMDX, with a consensus "Buy" rating and a target price above the current market price.
*   **Mixed News:** While there are reports of positive analyst sentiment and increased institutional investment, there are also articles highlighting concerns about future growth and insider sales, which requires careful monitoring.
*   **Technical Indicators:** The RSI indicates that the stock might be oversold, while the PPO shows a downward trend. The Hybrid Signal is a "Buy".
*   **Organ Transplantation Market:** TMDX operates in the organ transplantation market. Future growth is tied to its technology adoption and the growth in transplant procedures.
* **Expected High Returns:** the projected 49.8% expected return is substantial, indicating strong potential for long-term investment.

**Overall:** TMDX presents an interesting investment opportunity, especially given the strong analyst ratings and the expected high return, but potential investors should be aware of the inherent risks associated with high-growth, volatile stocks and conduct thorough due diligence. The recent uptick in price, coupled with an oversold RSI, might indicate a favorable entry point, but the short-term decline in relative divergence warrants attention.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.